ArticleJournal of nanobiotechnology2025
Carbon dot-lipidoid nanocarriers for superiorly biocompatible nasal mRNA cancer vaccination.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In this study, we synthesized an ionizable lipidoid, Cdoids, composed of carbon dots (Cdots) conjugated with oleic acid that exhibits superior biocompatibility compared to conventional ionizable lipids while retaining intrinsic fluorescence for real-time tracking and optimal nasal delivery of mRNA cancer vaccines. These properties make Cdoids a promising candidate for lipid nanoparticle (LNP) formulations. Incorporating Cdoids into LNPs enhances mRNA delivery efficiency via intranasal (IN) administration, providing a viable alternative to intramuscular (IM) injection. The unique structural features of Cdoids facilitate the formation of stable nanoparticles that efficiently encapsulate and deliver mRNA leveraging the immunological environment of the nasal mucosa to induce robust systemic and localized immune responses. Notably, Cdoids broaden the range of endocytosis mechanisms beyond conventional LNPs, leading to significantly enhanced mRNA expression within target cells. Comparative analyses demonstrated that Cdoids surpass commercially available ionizable lipids, such as SM-102, in both mRNA delivery efficiency and safety, exhibiting lower cytotoxicity in vitro and improved mRNA expression in vivo following IN administration. Furthermore, when applied as an mRNA cancer vaccine platform, Cdoids-based LNPs elicited strong antigen-specific immune responses, leading to effective tumor growth suppression. This study highlights the potential of Cdoids as an advanced ionizable lipid for LNP-based mRNA therapeutics and introduces an innovative strategy for optimizing intranasal vaccine delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.